Citation: Michael Kreuter,David J. Lederer,Maria Molina-Molina,Imre Noth,Claudia Valenzuela,Lutz Frankenstein,Derek Weycker,Mark Atwood,Klaus-Uwe Kirchgaessler,Vincent Cottin, (2019). Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. CHEST, Volume 156, Issue 4, October 2019, Pages 706-714. https://www.sciencedirect.com/science/article/pii/S0012369219308827 Background Angiotensin peptides have been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis. Angiotensin modulators are used to treat arterial hypertension, a frequent comorbidity of IPF. […]
Category: Antifibrotic therapies
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat Toby M. Maher1,2* and Mary E. Strek3 Correspondence: t.maher@rbht.nhs.uk1National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London,SW3 6NP, UK2Fibrosis Research Group, National Heart and Lung Institute, Imperial College, Cale Street, London SW3 6LY, UKFull list of […]
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Idiopathic Pulmonary Fibrosis (IPF): An Overview Shaney L. Barratt 1,2,*, Andrew Creamer 1, Conal Hayton 3 and Nazia Chaudhuri 3 1 Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol BS10 5NB, UK;andrew.creamer@nbt.nhs.uk2 Academic Respiratory Unit, University of Bristol, Bristol BS16 1QY, UK3 North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, […]